Plasma Metabolome Alterations Associated with Extrauterine Growth Restriction
Por:
Dudzik D, Iglesias-Platas I, Izquierdo-Renau M, Balcells-Esponera C, Del Rey Hurtado de Mendoza B, Lerin C, Ramon-Krauel M and Barbas C
Publicada:
1 abr 2020
Ahead of Print:
23 abr 2020
Resumen:
Very preterm infants (VPI, born at or before 32 weeks of gestation) are at risk of adverse health outcomes, from which they might be partially protected with appropriate postnatal nutrition and growth. Metabolic processes or biochemical markers associated to extrauterine growth restriction (EUGR) have not been identified. We applied untargeted metabolomics to plasma samples of VPI with adequate weight for gestational age at birth and with different growth trajectories (29 well-grown, 22 EUGR) at the time of hospital discharge. A multivariate analysis showed significantly higher levels of amino-acids in well-grown patients. Other metabolites were also identified as statistically significant in the comparison between groups. Relevant differences (with corrections for multiple comparison) were found in levels of glycerophospholipids, sphingolipids and other lipids. Levels of many of the biochemical species decreased progressively as the level of growth restriction increased in severity. In conclusion, an untargeted metabolomic approach uncovered previously unknown differences in the levels of a range of plasma metabolites between well grown and EUGR infants at the time of discharge. Our findings open speculation about pathways involved in growth failure in preterm infants and the long-term relevance of this metabolic differences, as well as helping in the definition of potential biomarkers.
Filiaciones:
Dudzik D:
Centro deMetabolómica y Bioanálisis, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain
Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdansk, 80-416 Gdansk, Poland
Iglesias-Platas I:
Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Izquierdo-Renau M:
Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Balcells-Esponera C:
Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Del Rey Hurtado de Mendoza B:
Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Lerin C:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Ramon-Krauel M:
Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain
Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
Barbas C:
Centro deMetabolómica y Bioanálisis, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain
Green Submitted, gold
|